Neuland says its own growth number isn't guidance. It might be right not to promise it.

I read 12 quarters of Neuland Laboratories transcripts and decks, plus 8 broker notes, one commitment at a time, to build the guidance section for it — the first time I've done that at this depth for this company. The near-term growth is safe and preordained. The money it throws off is funding something the company itself calls unproven.

The record first. 46 commitments tracked from Q2 FY24 to Q1 FY27. Of the financial guides that have closed, 4 of 6 were met or beaten — adequate delivery. Of 23 dated commitments, 5 have slipped, once each — reliable timing. Both misses are the same year, FY25, on revenue and on margin, and both were guides management had already cut once before missing anyway.

That's scored the same way for every company on this site: arithmetic, not framing. A guide of "a slight drop" that actually delivers a 730-basis-point margin collapse is written up as a miss, whatever the call transcript called it at the time.

What Neuland guides

Neuland has a policy, stated on the record in Q4 FY26: "we have not given formal guidance in the past that we do not intend to do so going forward." What it gives instead is a direction plus a base year, and a long-run aspiration it explicitly refuses to convert into a hard annual number.

• Long-run growth aspiration: 18-20% a year, over a 5-year period. First stated in Q3 FY24 as "about 20%," and in the very same call flagged as not a real commitment. Widened slightly to "18-20%" by Q4 FY26, where management said outright: "I always talk about it as aspirational."
• EBITDA margin anchor: 25% plus, long-term. "Anything that's above that is kind of a bonus."
• FY26, in year: "strong growth" off the FY24 base, not FY25 — a deliberate reframing after FY25 came in weak.

Every quarter in the window carries at least one explicit refusal to quantify further: FY25 margin ("we have decided not to quantify anything further"), quarterly phasing ("we really don't wish to break things down at a quarterly level"), the order book ("we've always been reluctant to fully reveal what the order book is").

The story is how

Strip away the aspiration and the near-term growth Neuland actually guides for is, in its own words, preordained — carried by molecules already commercial and capacity already built. That's the safe leg. The real bet is what all that cash is funding.

1. The safe leg: CMS and existing GDS molecules. CMS crossed above 50% of revenue in Q2 FY26 and over two-thirds by Q4 FY26 — a guide management set and cleared. "Our growth for the next 2 to 3 years is kind of preordained the fact that these products are already there," management said on the Q3 FY26 call.
2. The unproven leg: a peptide reactor expansion. Announced at ₹254 crore, restated at ₹300 crore, bracketed since by a ₹250-280 crore Module 1+2 ballpark — the same programme, not three separate ones. Reactor capacity is going from 0.5 KL to 6.37 KL, roughly 12x. The facility is built and funded. Commissioning has already slipped about two months — "ready by July, no change in the date" in Q4 FY26, then "commissioned next month," around September, in Q1 FY27. Management's own words: it has no firm contracts for the facility yet.
3. The R&D bet behind it. A new 140,000 sq ft R&D centre in Genome Valley, Hyderabad, first board-approved in Q3 FY26 and still on track as of Q1 FY27 — the infrastructure for whatever the peptide facility is supposed to produce next.

The one number

Not a percentage — a sentence. "Unit 3 utilisation levels have recently started ramping up" appears byte-for-byte in all 12 investor decks I read, from Q2 FY24 to Q1 FY27, unchanged. In that same window the company separately reported the site anywhere from 57% to over 90% utilisation, on different denominators, in different calls. The line never moved. What actually changed underneath it never got reconciled in the company's own materials — that's the number I'd want fixed before any of the growth percentages.

Where the record is weak

The two-year gap nobody's closed. Neuland's own long-run pitch is 18-20% annual growth. The actual FY24-to-FY26 compound rate, on reported figures, is 14.3%. On the Q4 FY26 call, an investor did that exact math and put it to management directly — "about roughly 10% compounded." Management didn't correct the number. Didn't confirm it either. Redirected to the 18-20% aspiration instead.

The FY25 double miss. Revenue guided as "relatively flat" (cut down from "modest growth") delivered -4.7%. EBITDA margin guided as "a slight drop" off FY24's ~30% delivered 22.9% — a 730-basis-point fall, not slight by any reading.

A transcript-integrity question, resolved on the record. On the Q4 FY26 call, an individual investor alleged that wording in the Q3 FY26 transcript had been altered from the posted audio. The company opened the following call with an answer: the full unedited audio is published, the third-party transcript agency's edits were for readability, and the disputed section was unchanged. Worth noting, because it's the kind of question a credibility read exists to take seriously — and here, the company answered it directly rather than letting it sit.

What the live book rests on

Of 29 open commitments, 7 are backed by something already signed, funded or built — the peptide capex itself, the R&D centre, existing CMS capacity. 15 rest on management's word for a defined horizon with no external backing cited. 7 are softer aspirations the company itself flags as long-range or not-guidance. That's a book with essentially no net tilt toward hard evidence, close to what "guidance resting mostly on management's say-so" looks like on paper. The ambition itself reads as measured, not stretched: the 18-20% long-run number sits above the delivered 14.3% two-year rate but below FY26's actual 37.1% print, so it isn't asking for more than the company has recently shown it can do — just more than it's shown on average.

What I'm not claiming

• I can't independently verify "no firm contracts yet" beyond management saying so — it could change on the next call, in either direction.
• Whether the COPD molecule described in Q4 FY25 and the one described as "just entering Phase 3" in Q1 FY26 are the same drug is never stated by the company, and I'm carrying that ambiguity rather than resolving it myself.
• A same-quarter deck disclosure of "2 new DMFs" vs "3 new USDMFs filed in FY26" is a real, unreconciled contradiction in Neuland's own materials, not mine to settle.
• This is a note about how Neuland guides, not investment advice.

What I'll be watching

• Whether the peptide facility's September commissioning date holds, and whether a first customer contract shows up before or after it does.
• Whether the 18-20% long-run number ever gets a year attached to it, or stays aspirational indefinitely.
• Whether the FY24-to-FY26 compound-growth question comes up again on a future call, and whether it gets a real answer this time.
• The R&D centre's opening date, and what it's actually meant to produce.

The full ledger, with every quote and the quarter it was made, is on the Neuland guidance page.